173 filings
Page 3 of 9
6-K
7lva3fp2i
9 Aug 22
MediWound Reports Second Quarter 2022 Financial Results and Provides
7:35am
6-K
8khv pe5y81wc
8 Aug 22
MediWound Enhances Its Board and Executive Leadership Team
4:10pm
6-K
6ie7wf4d
3 Aug 22
MediWound Announces U.S. FDA Acceptance of Biologics License
7:35am
6-K
q62p4a50sx
19 Jul 22
Current report (foreign)
4:05pm
6-K
j4izgc7yul26kf8 7j7
12 Jul 22
Current report (foreign)
4:05pm
6-K
p76fdrhth53sdn6v
11 Jul 22
MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005
7:05am
6-K
g2uz5d5
7 Jul 22
MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of
7:05am
6-K
8zii8
30 Jun 22
MediWound Names Mr. Tzvi Palash as Chief Operating Officer
7:05am
6-K
yrurrg6 gv55
9 Jun 22
Current report (foreign)
7:04am
6-K
6jgzc tonw
17 May 22
MediWound Announces CEO Transition
7:06am
6-K
nmupsxvlai qn2l
17 May 22
MediWound Reports First Quarter 2022 Financial Results
7:05am
6-K
qfde7d
12 May 22
MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
7:04am
6-K
nsmfy k353
22 Mar 22
MediWound Announces Exercise of Over-Allotment Option
4:10pm
6-K
2j6zy3x1okigsu
17 Mar 22
MediWound Reports Fourth Quarter and Full Year 2021 Financial Results
7:05am
6-K
nx6svk2ui7ioy
3 Mar 22
MediWound Announces Pricing of Public Offering of Ordinary Shares
4:09pm
6-K
ljkeys
2 Mar 22
MediWound Ltd. Announces Proposed Public Offering of Ordinary Shares
4:33pm
6-K
ur0j 9rsi7x5
10 Feb 22
MediWound Announces Additional $9 Million in Funding from BARDA to Support
7:05am
6-K
girndh 03l
24 Jan 22
MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
6:05am
6-K
p9jrwc2
20 Dec 21
MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of
7:05am
6-K
s7zuxf29kntklirpkj
6 Dec 21
MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study
7:05am